D ynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

Results from the first part of a Phase I/II trial (NCT06569823) showed that Z-1018 generated immune responses comparable to ...

Shares in Dynavax Technologies Corporation closed 5% higher Thursday after the presentation of positive top-line results from ...

Dynavax Technologies (NASDAQ:DVAX) added ~7% in the premarket on Thursday after the company said that its experimental ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

After paying almost $200 to get a shingles vaccine they later learned is publicly funded, a Tillsonburg, Ont., couple says ...

She was able to get the popular new shingles vaccine, Shingrix, at her Rite Aid pharmacy in Taylor without having to go on a waiting list. "I am a Type-2 diabetic, so it’s good for me to do the ...

Shingrix's efficacy rate is more than 90%, according to GSK. Experts recommend anyone who wants Shingrix to get on the waitlist at a pharmacy, clinic or doctor's office.